Status:
COMPLETED
Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborating Sponsors:
AstraZeneca
Fox Chase Cancer Center
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aims to determine if web-based eHealth delivery of pre-test and/or post-test counseling in cancer patients and/or those at risk for cancer can provide equal or improved cognitive and affect...
Detailed Description
Cancer genetic testing has become a standard evidence-based practice, with established risk reduction and cancer screening guidelines for genetic carriers. With FDA approval for PARP inhibitors in pat...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Speak and understand English
- Male or Female
- A personal history of one or more of the following:
- metastatic breast cancer
- advanced ovarian cancer (Stage III-IV)
- metastatic pancreatic cancer
- metastatic prostate cancer
- Naive to previous cancer germline genetic testing
Exclusion
- Communication difficulties such as:
- Uncorrected or uncompensated hearing and/or vision impairment
- Uncorrected or uncompensated speech defects
- Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks
Key Trial Info
Start Date :
August 17 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 13 2025
Estimated Enrollment :
256 Patients enrolled
Trial Details
Trial ID
NCT04353973
Start Date
August 17 2020
End Date
February 13 2025
Last Update
July 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104